Prolonged duration of response in lenvatinib responders with thyroid cancer

We present an updated analysis of lenvatinib in radioiodine-refractory differentiated thyroid cancer (RR-DTC) with new duration of response (DOR) data unavailable for the primary analysis. In this randomized, double-blind, multicenter, placebo-controlled phase 3 study, patients ≥18 years old with me...

Descripción completa

Detalles Bibliográficos
Autores principales: Gianoukakis, Andrew G, Dutcus, Corina E, Batty, Nicolas, Guo, Matthew, Baig, Mahadi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5958278/
https://www.ncbi.nlm.nih.gov/pubmed/29752332
http://dx.doi.org/10.1530/ERC-18-0049

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5958278/
https://www.ncbi.nlm.nih.gov/pubmed/29752332
http://dx.doi.org/10.1530/ERC-18-0049

Ejemplares similares